TX judges send Wyeth back to court; Health Canada criticized for "speeding up" approvals;

> Wyeth, the drugmaker being acquired by Pfizer, must face a lawsuit by a woman who claims her breast cancer was caused by the menopause medicine Prempro, a Texas appeals court ruled. Report

> A pharma industry critic says Health Canada puts too much emphasis on speeding up drug approvals and too little on following up on safety after drugs hit the market. Report

> Merrill Lynch cut its rating on AstraZeneca stock to "underperform" from "neutral" because of "relatively weaker long-term fundamentals." Report

> Pfizer invited investors and the public to tune in to a webcast of its annual shareholders meeting at 8:30 a.m. Thursday. Release

> Retail drug sales in India leapt by 18.4 percent in March after a 13.3 percent rise in February. Report

>Par Pharmaceutical said it resolved patent litigation with Reliant Pharmaceuticals with a settlement that allows Par to product a generic version of Reliant's Rhythmol product beginning in 2011. Release

> PricewaterhouseCoopers and the National Venture Capital Association have issued their quarterly report on the state of the venture capital market. Report

> Shares of Discovery Laboratories plunged today as the FDA announced that it wouldn't approve the company's drug Surfaxin for treatment of respiratory illness in infants. Report

> Pharmasset announced that the company has halted a late-stage study for its experimental chronic hepatitis B treatment clevudine. The news sent Pharmasset's shares tumbling nearly 14 percent in morning trading. Report

> With the public markets closed and venture funds in short supply, BIOTECanada is calling for more government support of the Canadian life science industry. Report

> Belgium's Galapagos says it's inked a deal with Merck in which Galapagos will use its SilenceSelect target discovery platform to identify inflammatory disease targets. Report

> The newly approved stimulus package includes $1.3 billion for cancer research in 2009 and 2010, and the head of the National Cancer Institute says that money will go a long way toward doubling the number of research grants that it approves. Report

> For years stem cell researchers have complained that federal guidelines limited the number of embryonic stem cell lines they could work with to a tiny selection. But all of that is about to change. Report

> A team of researchers at Cancer Research Technology says that a new drug that targets PKD in tumors has demonstrated a promising ability to target pancreatic and lung cancer. Report

And Finally... Next week, ex-FDA chief Dr. David Kessler premieres a book highlighting his research into "conditioned hypereating" of fatty, sugary foods. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.